FULGENT GENETICS INC (FLGT) Fundamental Analysis & Valuation

NASDAQ:FLGT • US3596641098

13.99 USD
+0.2 (+1.45%)
At close: Mar 4, 2026
14.1 USD
+0.11 (+0.79%)
Pre-Market: 3/5/2026, 4:00:00 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This FLGT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

FLGT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. FLGT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FLGT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. FLGT Profitability Analysis

1.1 Basic Checks

  • In the past year FLGT was profitable.
  • FLGT had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: FLGT reported negative net income in multiple years.
  • Of the past 5 years FLGT 4 years had a positive operating cash flow.
FLGT Yearly Net Income VS EBIT VS OCF VS FCFFLGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • The Return On Assets of FLGT (-3.54%) is worse than 60.40% of its industry peers.
  • FLGT has a Return On Equity (-3.82%) which is in line with its industry peers.
Industry RankSector Rank
ROA -3.54%
ROE -3.82%
ROIC N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
FLGT Yearly ROA, ROE, ROICFLGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30 40

1.3 Margins

  • FLGT has a better Gross Margin (41.24%) than 70.30% of its industry peers.
  • FLGT's Gross Margin has declined in the last couple of years.
  • FLGT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
FLGT Yearly Profit, Operating, Gross MarginsFLGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. FLGT Health Analysis

2.1 Basic Checks

  • FLGT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for FLGT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FLGT Yearly Shares OutstandingFLGT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
FLGT Yearly Total Debt VS Total AssetsFLGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 4.09 indicates that FLGT is not in any danger for bankruptcy at the moment.
  • FLGT's Altman-Z score of 4.09 is fine compared to the rest of the industry. FLGT outperforms 76.24% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that FLGT is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.00, FLGT belongs to the top of the industry, outperforming 87.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.09
ROIC/WACCN/A
WACC8.7%
FLGT Yearly LT Debt VS Equity VS FCFFLGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • FLGT has a Current Ratio of 7.01. This indicates that FLGT is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 7.01, FLGT belongs to the best of the industry, outperforming 97.03% of the companies in the same industry.
  • A Quick Ratio of 7.01 indicates that FLGT has no problem at all paying its short term obligations.
  • FLGT has a better Quick ratio (7.01) than 97.03% of its industry peers.
Industry RankSector Rank
Current Ratio 7.01
Quick Ratio 7.01
FLGT Yearly Current Assets VS Current LiabilitesFLGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. FLGT Growth Analysis

3.1 Past

  • The earnings per share for FLGT have decreased strongly by -16.33% in the last year.
  • The earnings per share for FLGT have been decreasing by -45.36% on average. This is quite bad
EPS 1Y (TTM)-16.33%
EPS 3Y-58.41%
EPS 5Y-45.36%
EPS Q2Q%300%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%9.34%

3.2 Future

  • FLGT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -67.05% yearly.
  • Based on estimates for the next years, FLGT will show a quite strong growth in Revenue. The Revenue will grow by 10.44% on average per year.
EPS Next Y-179.61%
EPS Next 2Y-54.32%
EPS Next 3Y-67.05%
EPS Next 5YN/A
Revenue Next Year7.81%
Revenue Next 2Y9.97%
Revenue Next 3Y10.44%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
FLGT Yearly Revenue VS EstimatesFLGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
FLGT Yearly EPS VS EstimatesFLGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. FLGT Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 34.12, the valuation of FLGT can be described as expensive.
  • The rest of the industry has a similar Price/Earnings ratio as FLGT.
  • The average S&P500 Price/Earnings ratio is at 27.03. FLGT is valued slightly more expensive when compared to this.
  • FLGT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 34.12
Fwd PE N/A
FLGT Price Earnings VS Forward Price EarningsFLGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FLGT Per share dataFLGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • FLGT's earnings are expected to decrease with -67.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-54.32%
EPS Next 3Y-67.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FLGT Dividend Analysis

5.1 Amount

  • No dividends for FLGT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FLGT Fundamentals: All Metrics, Ratios and Statistics

FULGENT GENETICS INC

NASDAQ:FLGT (3/4/2026, 8:26:12 PM)

Premarket: 14.1 +0.11 (+0.79%)

13.99

+0.2 (+1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-27
Earnings (Next)04-30
Inst Owners57.31%
Inst Owner Change12.43%
Ins Owners32.7%
Ins Owner Change3.99%
Market Cap436.91M
Revenue(TTM)N/A
Net Income(TTM)-42.98M
Analysts80
Price Target34.34 (145.46%)
Short Float %7.54%
Short Ratio5.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)149.45%
Min EPS beat(2)137.43%
Max EPS beat(2)161.46%
EPS beat(4)4
Avg EPS beat(4)137.97%
Min EPS beat(4)121.2%
Max EPS beat(4)161.46%
EPS beat(8)8
Avg EPS beat(8)161.48%
EPS beat(12)11
Avg EPS beat(12)118.12%
EPS beat(16)15
Avg EPS beat(16)122.7%
Revenue beat(2)2
Avg Revenue beat(2)3.23%
Min Revenue beat(2)1.21%
Max Revenue beat(2)5.24%
Revenue beat(4)3
Avg Revenue beat(4)1.43%
Min Revenue beat(4)-1.8%
Max Revenue beat(4)5.24%
Revenue beat(8)5
Avg Revenue beat(8)0.7%
Revenue beat(12)9
Avg Revenue beat(12)5.2%
Revenue beat(16)13
Avg Revenue beat(16)7.57%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)180.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.43%
Valuation
Industry RankSector Rank
PE 34.12
Fwd PE N/A
P/S 1.38
P/FCF N/A
P/OCF 286.87
P/B 0.39
P/tB 0.45
EV/EBITDA N/A
EPS(TTM)0.41
EY2.93%
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)0.05
OCFY0.35%
SpS10.1
BVpS36.05
TBVpS30.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number18.24
Profitability
Industry RankSector Rank
ROA -3.54%
ROE -3.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 41.24%
FCFM N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
F-Score7
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.3%
Cap/Sales 6.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.01
Quick Ratio 7.01
Altman-Z 4.09
F-Score7
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)101.39%
Cap/Depr(5y)338.11%
Cap/Sales(3y)8.31%
Cap/Sales(5y)7.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.33%
EPS 3Y-58.41%
EPS 5Y-45.36%
EPS Q2Q%300%
EPS Next Y-179.61%
EPS Next 2Y-54.32%
EPS Next 3Y-67.05%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%9.34%
Revenue Next Year7.81%
Revenue Next 2Y9.97%
Revenue Next 3Y10.44%
Revenue Next 5YN/A
EBIT growth 1Y19.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year90.23%
EBIT Next 3Y8.71%
EBIT Next 5Y11.31%
FCF growth 1Y-192.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.64%
OCF growth 3Y-66.06%
OCF growth 5Y30.8%

FULGENT GENETICS INC / FLGT FAQ

Can you provide the ChartMill fundamental rating for FULGENT GENETICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to FLGT.


Can you provide the valuation status for FULGENT GENETICS INC?

ChartMill assigns a valuation rating of 0 / 10 to FULGENT GENETICS INC (FLGT). This can be considered as Overvalued.


Can you provide the profitability details for FULGENT GENETICS INC?

FULGENT GENETICS INC (FLGT) has a profitability rating of 2 / 10.


Can you provide the financial health for FLGT stock?

The financial health rating of FULGENT GENETICS INC (FLGT) is 6 / 10.


Can you provide the expected EPS growth for FLGT stock?

The Earnings per Share (EPS) of FULGENT GENETICS INC (FLGT) is expected to decline by -179.61% in the next year.